The estimated Net Worth of Natasha Giordano is at least $913 Thousand dollars as of 15 March 2022. Ms Giordano owns over 4,100 units of PLx Pharma stock worth over $207 and over the last 8 years she sold PLXP stock worth over $0. In addition, she makes $912,328 as CEO and Pres & Director at PLx Pharma.
Ms has made over 1 trades of the PLx Pharma stock since 2022, according to the Form 4 filled with the SEC. Most recently she bought 4,100 units of PLXP stock worth $14,965 on 15 March 2022.
The largest trade she's ever made was buying 4,100 units of PLx Pharma stock on 15 March 2022 worth over $14,965. On average, Ms trades about 315 units every 0 days since 2016. As of 15 March 2022 she still owns at least 5,186 units of PLx Pharma stock.
You can see the complete history of Ms Giordano stock trades at the bottom of the page.
Natasha Giordano is the CEO, Pres & Director at PLx Pharma.
As the CEO and Pres & Director of PLx Pharma, the total compensation of Ms Giordano at PLx Pharma is $912,328. There are no executives at PLx Pharma getting paid more.
Ms Giordano is 61, she's been the CEO and Pres & Director of PLx Pharma since . There are 8 older and 4 younger executives at PLx Pharma. The oldest executive at PLx Pharma Inc. is Patrick M. Lonergan, 86, who is the Member of Chief Exec. Officer Advisory Group.
Natasha's mailing address filed with the SEC is C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH SUITE 302, BEDMINSTER,, NJ, 07921.
Over the last 8 years, insiders at PLx Pharma have traded over $0 worth of PLx Pharma stock and bought 841,160 units worth $2,548,334 . The most active insiders traders include West Asset Management Llc Park, Michael J Valentino, and David Emerson Jorden. On average, PLx Pharma executives and independent directors trade stock every 124 days with the average trade being worth of $2,403. The most recent stock trade was executed by Natasha Giordano on 15 March 2022, trading 4,100 units of PLXP stock currently worth $14,965.
PLx Pharma Inc. is a late-stage specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effective and safer products. The PLxGuard drug delivery platform works by targeting the release of active pharmaceutical ingredients to various portions of the gastrointestinal (GI) tract. PLx believes this has the potential to improve the absorption of many drugs currently on the market or in development, and to reduce the risk of stomach erosions and ulcers associated with aspirin and ibuprofen, and potentially other drugs.
PLx Pharma executives and other stock owners filed with the SEC include: